Bioline Launches New JetSeq DNA Quantification Kits
March 27 2017 - 10:32AM
CINCINNATI, March 27, 2017 (GLOBE
NEWSWIRE) -- Bioline, The PCR Company, a wholly-owned subsidiary of
Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the further
expansion of the JetSeq(TM) portfolio for Next Generation
Sequencing (NGS) sample preparation.
The new JetSeq(TM) Library
Quantification Kit is a qPCR-based assay that provides fast,
accurate and sensitive quantification of adaptor-ligated DNA
fragments during the preparation of Illumina compatible NGS
libraries. The JetSeq(TM) Library Quantification Kit relies on
SYBR®1 Green I
for detection and contains all of the components required for
library quantification, including dilution buffer, P5 and P7
adapter primers and six pre-diluted DNA standards to minimize
pipetting, reduce variability and thereby increase reproducibility.
The kit has sufficient standards to quantify eighteen libraries on
individual plates or up to seventy-six libraries when multiple
libraries are quantified on the same plate.
Marco Calzavara, President of Bioline
commented, "The release of the new JetSeq(TM) Library
Quantification Kit compliments the JetSeq(TM) Library preparation
kits that Bioline launched last month, moving us even further into
the NGS space. The kit builds on our extensive knowledge in qPCR,
providing a fast, sensitive and reliable solution to determine
library concentrations, giving customers confidence in the cluster
density loaded on Illumina sequencing platforms."
Richard L. Eberly, President, Chief
Commercial Officer, stated, "We are pleased to announce the release
of the new JetSeq(TM) Library Quantification Kit; this is an
important addition to our ever-increasing portfolio of NGS products
and gives our life science customers greater confidence in the
quantification of their sequencing libraries. The further
development of the JetSeq(TM) family shows our commitment, not just
to the continued development and expansion of products from
Bioline, but also to our customers, giving them a greater support
around this fast-growing market."
About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops,
manufactures, markets and distributes a broad range of innovative
diagnostic test kits, rare reagents, specialty biologicals and
components. Utilizing a variety of methods, our diagnostic tests
provide accuracy, simplicity and speed in the early diagnosis and
treatment of common medical conditions, such as infections and lead
poisoning. Meridian's diagnostic products are used outside of the
human body and require little or no special equipment. The
Company's diagnostic products are designed to enhance patient
well-being while reducing the total outcome costs of health care.
Meridian has strong market positions in the areas of
gastrointestinal and upper respiratory infections and blood lead
level testing. In addition, Meridian is a supplier of rare
reagents, specialty biologicals and components used by
organizations in the life science and agribio industries engaged in
research and by companies as components in the manufacture of
diagnostics. The Company markets its products and technologies to
hospitals, reference laboratories, research centers, diagnostics
manufacturers and agribio companies in more than 70 countries
around the world. The Company's shares are traded on the NASDAQ
Global Select Market, symbol VIVO. Meridian's website address
is www.meridianbioscience.com.
FOR ADDITIONAL INFORMATION:
For more information about Bioline, please
visit http://www.bioline.com.
1 SYBR is
a registered trademark of Thermo Fisher Scientific.
CONTACT:
Richard L. Eberly
President, Chief Commercial Officer
Meridian Bioscience, Inc.
Phone: 513.271.3700
Rick.eberly@meridianbioscience.com
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Meridian Bioscience, Inc. via Globenewswire
Meridian Bioscience (NASDAQ:VIVO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Meridian Bioscience (NASDAQ:VIVO)
Historical Stock Chart
From Mar 2023 to Mar 2024